中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
17期
78-80
,共3页
急性冠脉综合征%氯吡格雷%sCD40L%剂量%浓度
急性冠脈綜閤徵%氯吡格雷%sCD40L%劑量%濃度
급성관맥종합정%록필격뢰%sCD40L%제량%농도
Acute coronary syndrome%Clopidogrel%sCD40L%Dosage%Concentration
目的 观察不同剂量氯吡格雷对非ST段抬高型急性冠脉综合征患者Scd40L水平的影响.方法 选取2012年2月至2014年2月于濮阳市人民医院接受治疗的120例冠心病患者作为研究对象,其中SAP(稳定型心绞痛)组50例,NST-ACS(非ST段抬高型急性冠脉综合征)组70例,随机将SAP患者分为A组(n=20)与B组(n=30),均给予氯吡格雷治疗,A组75 mg/d,B组150 mg/d.NST-ACS组给予氯吡格雷300 mg后分为C组(n=35)与D组(n=35),均给予氯吡格雷维持,C组75 mg/d,D组150 mg/d.同时选取30例作为正常对照组,不给予任何药物治疗.于服药前后取患者静脉外周血液样本,测定血清sCD40L水平.结果 服药前,C组血清sCD40L水平为(804.55±257.25) pg/ml,D组为(860.72±154.85) pg/ml,两组比较差异未见统计学意义,与A、B两组比较差异有统计学意义(P＜0.05),且A、B、C、D四组服药前血清sCD40L浓度水平均明显高于对照组(P＜0.05),负荷量ld后,C、D两组血清sCD40L浓度水平明显降低,与服药前比较差异有统计学意义(P＜0.05),服药5d后,A组sC D40L浓度为(630.31±238.57)pg/ml,与B组比较差异未见统计学意义,与C、D两组比较差异有统计学意义(P＜0.05).结论 正常健康人血清内sCD40L水平明显低于NST-ACS患者,采用氯吡格雷治疗可有效抑制血小板活化,降低患者血清sCD40L水平,降低治疗的危险性,优化治疗效果,值得推广.
目的 觀察不同劑量氯吡格雷對非ST段抬高型急性冠脈綜閤徵患者Scd40L水平的影響.方法 選取2012年2月至2014年2月于濮暘市人民醫院接受治療的120例冠心病患者作為研究對象,其中SAP(穩定型心絞痛)組50例,NST-ACS(非ST段抬高型急性冠脈綜閤徵)組70例,隨機將SAP患者分為A組(n=20)與B組(n=30),均給予氯吡格雷治療,A組75 mg/d,B組150 mg/d.NST-ACS組給予氯吡格雷300 mg後分為C組(n=35)與D組(n=35),均給予氯吡格雷維持,C組75 mg/d,D組150 mg/d.同時選取30例作為正常對照組,不給予任何藥物治療.于服藥前後取患者靜脈外週血液樣本,測定血清sCD40L水平.結果 服藥前,C組血清sCD40L水平為(804.55±257.25) pg/ml,D組為(860.72±154.85) pg/ml,兩組比較差異未見統計學意義,與A、B兩組比較差異有統計學意義(P＜0.05),且A、B、C、D四組服藥前血清sCD40L濃度水平均明顯高于對照組(P＜0.05),負荷量ld後,C、D兩組血清sCD40L濃度水平明顯降低,與服藥前比較差異有統計學意義(P＜0.05),服藥5d後,A組sC D40L濃度為(630.31±238.57)pg/ml,與B組比較差異未見統計學意義,與C、D兩組比較差異有統計學意義(P＜0.05).結論 正常健康人血清內sCD40L水平明顯低于NST-ACS患者,採用氯吡格雷治療可有效抑製血小闆活化,降低患者血清sCD40L水平,降低治療的危險性,優化治療效果,值得推廣.
목적 관찰불동제량록필격뢰대비ST단태고형급성관맥종합정환자Scd40L수평적영향.방법 선취2012년2월지2014년2월우복양시인민의원접수치료적120례관심병환자작위연구대상,기중SAP(은정형심교통)조50례,NST-ACS(비ST단태고형급성관맥종합정)조70례,수궤장SAP환자분위A조(n=20)여B조(n=30),균급여록필격뢰치료,A조75 mg/d,B조150 mg/d.NST-ACS조급여록필격뢰300 mg후분위C조(n=35)여D조(n=35),균급여록필격뢰유지,C조75 mg/d,D조150 mg/d.동시선취30례작위정상대조조,불급여임하약물치료.우복약전후취환자정맥외주혈액양본,측정혈청sCD40L수평.결과 복약전,C조혈청sCD40L수평위(804.55±257.25) pg/ml,D조위(860.72±154.85) pg/ml,량조비교차이미견통계학의의,여A、B량조비교차이유통계학의의(P＜0.05),차A、B、C、D사조복약전혈청sCD40L농도수평균명현고우대조조(P＜0.05),부하량ld후,C、D량조혈청sCD40L농도수평명현강저,여복약전비교차이유통계학의의(P＜0.05),복약5d후,A조sC D40L농도위(630.31±238.57)pg/ml,여B조비교차이미견통계학의의,여C、D량조비교차이유통계학의의(P＜0.05).결론 정상건강인혈청내sCD40L수평명현저우NST-ACS환자,채용록필격뢰치료가유효억제혈소판활화,강저환자혈청sCD40L수평,강저치료적위험성,우화치료효과,치득추엄.
Objective To observe the effects of different doses of clopidogrel on Scd40L levels in patients with non ST segment elevation acute coronary syndrome.Methods One hundred and twenty patients with coronary heart disease from February 2012 to February 2014 were chose as the research objects,50 cases of SAP (stable angina),To cases of NST-ACS (non ST segment elevation acute coronary syndrome),SAP patients were divided into the group A (n =20) and group B (n=30).The patients in the two groups were given clopidogrel treatment,75 mg/d in group A,150 mg/d in group B.Mter give in clopidogrel 300 mg in 70 cases of NST-ACS,they were divided into the group C (n =35) and group (n =35) D,group C was given clopidogrel maintenance of 75 mg/d,group D with 150 mg/d.At the same time,30 cases were selected as the normal control group which was not given any drug treatment.Before and after treatment in patients with venous from peripheral blood samples for determination of serum sCD40L levels.Results Before treatment,the serum level of sCD40L in group C was (804.55 ±257.25) pg/ml,in group D was (860.72 ± 154.85) pg/ml,there was no significant difference between the two group,and differences between group A and group B were significant (P ＜ 0.05),The serum sCD40L levels of the four groups before medication were higher than that of the control group (P ＜ 0.05),load 1 d,serum sCD40L levels of group C and group D were significantly decreased,there was significant difference compared with before treatment (P ＜ 0.05),medication after 5d,the concentration of sCD40L of group A was (630.31 ± 238.57) pg/ml,there was no obvious difference with the group B,and difference between the two groups was significant (P ＜ 0.05).Conclusions Serum sCD40L level in healthy people was significantly lower than that of NST-ACS patients,and the use of clopidogrel therapy can effectively inhibit platelet activation,reduce the level of serum sCD40L,reduce the risk of treatment,optimize the therapeutic effect,is worthy of promotion.
